70cc710850b21f2cd1027a96d266b2e7aaf4081a

Kyowa Hakko USA Introduces New VELOX® Patented Performance Blend

Kyowa Hakko USA Introduces New VELOX® Patented Performance Blend


New branded ingredient VELOX® features novel patented amino acid combination backed by science
 New York, April 30, 2020 - Kyowa Hakko USA announces the launch of VELOX® Patented Performance Blend, a clinically studied combination of Kyowa’s L-Citrulline and Kyowa’s L-Arginine that has been shown to increase Nitric Oxide production and to boost Nitric Oxide levels more rapidly than L-Arginine alone*.

The unique blend comes backed by 4 U.S. Patents - U.S. Patent 8,609,735, U.S. Patent 9,060,980, U.S. Patent 9,622,998, and U.S. Patent 10,052,298 titled, “Rapid-acting, blood-arginine-level-increasable oral preparation comprising citrulline and arginine” which covers the use of ingredients and related compounds within the blend. The effective dosage requires a minimum of 1.2 grams of Kyowa’s L-Citrulline and 1.2 grams of Kyowa’s L-Arginine, and a ratio of 1:1 of Kyowa L-Citrulline and Kyowa L-Arginine to support claims.

“With four U.S. patents and clinical studies to support it, introducing this new performance blend to the market from Kyowa Hakko strengthens our position as a company that is committed to ensuring our customers always receive efficacious, ultra-pure, high-quality ingredients, guaranteed,” comments Elyse Lovett, MS, MBA, Senior Marketing Manager of Kyowa Hakko U.S.A. Inc.

VELOX® Patented Performance Blend is clinically studied to rapidly increase blood Arginine levels*, increase power output*, reduce muscle soreness*, and synergistically increase blood Arginine levels*. It is a patented Nitric Oxide booster* that is manufactured through Kyowa Hakko’s innovative fermentation process, ensuring purity and no added chemicals. The new branded ingredient is made in the USA, is non-GMO, and vegetarian. Citrulline is self-affirmed GRAS, Arginine is an FDA approved food additive therefore VELOX® Patented Performance Blend can be used in a wide variety of food, beverage, and dietary supplement applications.

“We couldn’t be more thrilled to incorporate VELOX® into Kyowa Hakko’s line of innovative branded health ingredients,” remarks Lovett, “We look forward to supporting our quest to improve health through our clinically-studied ingredients for nutraceuticals and food products worldwide.”

Customers interested in including VELOX® into their next product can contact Kyowa Hakko through their site form at https://kyowa-usa.com/branded-ingredients/velox-patented-performance-blend. Media interested in setting up an interview with a Kyowa Hakko representative to discuss the VELOX Patented Performance Blend, please contact Sara White: sara@adinnyc.com or 914-621.1323.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

About VELOX Patented Performance Blend:

VELOX® Patented Performance Blend is a combination of Kyowa’s L-Citrulline and Kyowa’s L-Arginine. The effective dosage requires a minimum of 1.2 grams of Kyowa’s L-Citrulline and 1.2 grams of Kyowa’s L-Arginine, and a ratio of 1:1 of Kyowa L-Citrulline and Kyowa L-Arginine to support claims. VELOX® Patented Performance Blend is clinically studied to rapidly increase blood Arginine levels*, increase power output*, reduce muscle soreness*, and synergistically increase blood Arginine levels*. VELOX ® is protected by four US Patents: U.S. Patent 8,609,735, U.S. Patent 9,060,980, U.S. Patent 9,622,998, and U.S. Patent 10,052,298

About Kyowa Hakko USA:

Kyowa Hakko USA is the North & South American office for Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing, and marketing of pharmaceuticals, nutraceuticals, and food products. For more information visit Kyowa-USA.com.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

References
1.    Suzuki T. et al. Biosci Biotechnol Biochem. 81(2): 372-375, 2017
2.    Suzuki I. et al. Eur J Appl Physiol. 2019


Media Contact:

ELYSE LOVETT
Kyowa Hakko
Phone: 9177967533

KYOWA HAKKO USA
600 Third Ave, 19th Floor
New York, NY 10016

Phone: 1-800-596-9252 or 212-319-5353
Email: info@kyowa-usa.com

Website: https://kyowa-usa.com/

Post a Comment

0 Comments